Aneurysm Cerebral Clinical Trial
— KEEPOfficial title:
Kaneka Endovascular Embolization and Protection
Prospective, multi-center, non-randomized registry / study, up to 164 patients enrolled and followed at 180 days +/- 45 days and again at 365 days +/- 90 days post procedure
Status | Recruiting |
Enrollment | 164 |
Est. completion date | October 2025 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Target aneurysm of 4mm - 14mm in size - Ruptured or unruptured - Suitable for embolization with coils - May be treated with or without assist devices Exclusion Criteria: - Unstable neurological deficit in unruptured cases (condition worsening within last 90 days) - Pre-planned staged procedure of target aneurysm - mRS score 3 or more - Hunt Hess Score more than 3 for subjects with ruptured aneurysm - Evidence of active infection (e.g.,fever, temperature >38 degrees C and/or WBC >15,000) |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic | Cleveland | Ohio |
United States | McLaren Health Care | Grand Blanc | Michigan |
United States | Northwell Health Lenox Hill Hospital | New York | New York |
United States | SSM Health St. Anthony's Hospital | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Kaneka Medical America LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adequate Occlusion | Proportion of subjects who achieve Adequate Occlusion (Modified Raymond-Roy I or II Classification) | 12 months | |
Secondary | Complete Occlusion | Complete occlusion at 1 year (Modified Raymond-Roy I) | 12 months | |
Secondary | Packing Density | Aneurysm volume and percent of aneurysm packing for coil embolization. Packing density will be evaluated based on aneurysm volume and coil volume | 12 months | |
Secondary | Modified Rankin Score | Modified Rankin Score (Scale from 0-6), the lower the score the better - 0 No symptoms and 6 is dead.
No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead |
12 months | |
Secondary | Retreatment | Any retreatment of the aneurysm, surgically or interventional embolization | 12 months | |
Secondary | Adverse events | Device or procedure related adverse events | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06033378 -
Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage.
|
N/A | |
Recruiting |
NCT05257824 -
Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling
|
Phase 4 | |
Enrolling by invitation |
NCT06215105 -
Complex Aneurysm Registry - Real-World Evidence Data Collection Intracranial Aneurysm Treatment Devices
|
||
Completed |
NCT03355534 -
Dexmedetomidine Improves Recovery After Cranial Aneurysm Surgery
|
N/A | |
Recruiting |
NCT05324605 -
Personalized Treatment Planning in Intracranial Aneurysm Surgeries.
|
||
Recruiting |
NCT05029947 -
Setting Benchmarks for Microsurgical Clipping of Unruptured Intracranial Aneurysms
|
||
Recruiting |
NCT06123325 -
Psychiatric Outcomes of Unruptured Intracranial Aneurysms (POUIA)
|
||
Enrolling by invitation |
NCT05441618 -
Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant®
|
||
Not yet recruiting |
NCT05419661 -
Interest of a Simulated Procedure Performed on a Printed Model in the Endovascular Treatment of Carotid-sylvian Aneurysms
|
N/A |